A Multicenter, Prospective, Single-Arm, Observational Study on Effectiveness and Safety of Lemborexant on Insomnia Patients With Psychiatric Disorders
This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score ≥11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-world evidence for the clinical optimization of treatment regimens for insomnia comorbid with psychiatric disorders.
• Aged 18 years and above, regardless of gender;
• Meet the DSM-5 diagnostic criteria for mental disorders (any type);
• Insomnia Severity Index (ISI) score ≥11;
• Have at least 7 hours of sleep time available;
• Able to complete the 2-month scale assessment and follow-up plan;
• Voluntarily sign the informed consent form;
• Intend to receive lemborexant treatment as judged by the clinicians